Story of a Stock

A fundamental screener that adds business story, management commentary, and qualitative context to the numbers.

Explore

Coverage Universe

How Scores Work

Connect

X (Twitter)Telegram group (opens in a new tab)Submit Request

Built by Pranav Yadav

Experimental research workflow for Indian equity scuttlebutt. Not investment advice.

Research platformStory of a Stock

Results·7 today

Story of a Stock

Results·7 today

Desk Filings Ranking Journal Scanners

Sign in Sign up

AARTI PHARMALABS LIMITED (AARTIPHARM) — concall analysis | Story of a Stock

AARTI PHARMALABS LIMITED

SoaS score

5.0/10

Weak & rich

Healthcare/API & CDMO

API, Xanthine derivatives & CDMO manufacturer for pharma & beverage industries. The engine is the Xanthine ramp to 80%+ by FY28, and momentum is building now that the print has firmed up, but the price already banks that ramp.

When a section on AARTI PHARMALABS LIMITED changes, it gets posted in the Telegram group first.

Join on Telegram→ (opens in a new tab)

AARTI PHARMALABS LIMITED

SoaS score

5.0/10

Weak & rich

Healthcare/API & CDMO

API, Xanthine derivatives & CDMO manufacturer for pharma & beverage industries. The engine is the Xanthine ramp to 80%+ by FY28, and momentum is building now that the print has firmed up, but the price already banks that ramp.

Leans bad

38 / 100

The goodThe bad

Valuation

The good

The bad

Where it sits

#186/205BELOW LINE